Vimarsana
Biggest News Aggregation in the World

Page 38 - Accessed August News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Accessed August. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Accessed August Today - Breaking & Trending Today

FDA Authorizes Intradermal Jynneos Monkeypox Outbreak - Vimarsana News

FDA Authorizes Intradermal Jynneos Monkeypox Outbreak

Under the Jynneos EUA, intradermal administration of the vaccine has been authorized in individuals 18 years of age and older.

Daiichi Sankyo: Datopotamab Deruxtecan-Based Combinations Show Promising Clinical Activity in Patients with Advanced Non-Small Cell Lung Cancer - Vimarsana News

Daiichi Sankyo: Datopotamab Deruxtecan-Based Combinations Show Promising Clinical Activity in Patients with Advanced Non-Small Cell Lung Cancer

Late-breaking oral presentation at WCLC features first results from TROPION-Lung02 trial of Daiichi Sankyo and AstraZeneca's TROP2 directed antibody drug conjugate Initial results from the TROPION-Lung02

New Indication for Nubeqa: Metastatic Hormone-Sensitive Prostate Cancer - Vimarsana News

New Indication for Nubeqa: Metastatic Hormone-Sensitive Prostate Cancer

The FDA has approved Nubeqa (darolutamide) plus docetaxel for the treatment of metastatic hormone-sensitive prostate cancer.

Datopotamab Deruxtecan-Based Combinations Show Promising Clinical Activity in Patients with Advanced Non-Small Cell Lung Cancer - Vimarsana News

Datopotamab Deruxtecan-Based Combinations Show Promising Clinical Activity in Patients with Advanced Non-Small Cell Lung Cancer

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Aug 9, 2022--

Enhertu Approved for HER2-Low Metastatic Breast Cancer - Vimarsana News

Enhertu Approved for HER2-Low Metastatic Breast Cancer

The FDA has approved Enhertu (fam-trastuzumab-deruxtecan-nxki) for adults with unresectable or metastatic HER2-low breast cancer.